APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Cancer Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Cancer Drugs Market Outlook and Growth Opportunities 2026

Report ID 173974260422 December 2025213 pages

Choose your research edition.

Industry ResearchCancer Drugs Industry Research Report 2026143 pages · $2,950 USDIndustry Growth & TrendsGlobal Cancer Drugs Industry Growth and Trends Forecast to 2032123 pages · $3,450 USDMarket StructureGlobal Cancer Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cancer Drugs Market Outlook and Growth Opportunities 2026213 pages · $4,250 USDMarket Analysis & ForecastGlobal Cancer Drugs Market Analysis and Forecast 2026-2032218 pages · $4,950 USD

Market perspective

The global Cancer Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Cancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Cancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Cancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Cancer Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Cancer Drugs market include Takeda, Eisai, Teva, Sanofi, Johnson & Johnson, Novartis, Roche, Eli Lilly and Pfizer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Cancer Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Cancer Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Cancer Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Cancer Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Cancer Drugs Segment by Company

Takeda

Eisai

Teva

Sanofi

Johnson & Johnson

Novartis

Roche

Eli Lilly

Pfizer

Bayer

Amgen

AbbVie

AstraZeneca

Otsuka

Merck KGaA

Merck & Co.

Ipsen

Gilead Sciences

Celgene

Bristol-Myers Squibb

Biogen Idec

Astellas

Cancer Drugs Segment by Type

Targeted Therapy

Hormonal Therapy (Biologic Therapy)

Chemotherapy

Immunotherapy

Others

Cancer Drugs Segment by Application

Blood Cancer

Gastrointestinal Cancer

Breast Cancer

Prostate Cancer

Respiratory/Lung Cancer

Other Cancers

Cancer Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Cancer Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Cancer Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Cancer Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Cancer Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cancer Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cancer Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cancer Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Cancer Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Cancer Drugs industry.

Chapter 3: Detailed analysis of Cancer Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Cancer Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Cancer Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Cancer Drugs Industry Trends Table 2. Cancer Drugs Industry Drivers Table 3. Cancer Drugs Industry Opportunities and Challenges Table 4. Cancer Drugs Industry Restraints Table 5. Global Cancer Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Cancer Drugs Revenue Share by Company (2021-2026) Table 7. Global Cancer Drugs Sales Volume by Company (k tons) & (2021-2026) Table 8. Global Cancer Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Cancer Drugs Average Price (US$/ton) of Company (2021-2026) Table 10. Global Cancer Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Cancer Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Cancer Drugs Company, Product Type & Application Table 13. Global Cancer Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Cancer Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Targeted Therapy Table 18. Significant Companies of Hormonal Therapy (Biologic Therapy) Table 19. Significant Companies of Chemotherapy Table 20. Significant Companies of Immunotherapy Table 21. Significant Companies of Others Table 22. Global Cancer Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (k tons) Table 23. Global Cancer Drugs Sales Volume by Type (2021-2026) & (k tons) Table 24. Global Cancer Drugs Sales Volume by Type (2027-2032) & (k tons) Table 25. Global Cancer Drugs Sales Volume Share by Type (2021-2026) Table 26. Global Cancer Drugs Sales Volume Share by Type (2027-2032) Table 27. Global Cancer Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Cancer Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Cancer Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Cancer Drugs Sales Value Share by Type (2021-2026) Table 31. Global Cancer Drugs Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Blood Cancer Table 33. Significant Companies of Gastrointestinal Cancer Table 34. Significant Companies of Breast Cancer Table 35. Significant Companies of Prostate Cancer Table 36. Significant Companies of Respiratory/Lung Cancer Table 37. Significant Companies of Other Cancers Table 38. Global Cancer Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (k tons) Table 39. Global Cancer Drugs Sales Volume by Application (2021-2026) & (k tons) Table 40. Global Cancer Drugs Sales Volume by Application (2027-2032) & (k tons) Table 41. Global Cancer Drugs Sales Volume Share by Application (2021-2026) Table 42. Global Cancer Drugs Sales Volume Share by Application (2027-2032) Table 43. Global Cancer Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 44. Global Cancer Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 45. Global Cancer Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 46. Global Cancer Drugs Sales Value Share by Application (2021-2026) Table 47. Global Cancer Drugs Sales Value Share by Application (2027-2032) Table 48. Global Cancer Drugs Sales by Region: 2021 VS 2025 VS 2032 (k tons) Table 49. Global Cancer Drugs Sales by Region (2021-2026) & (k tons) Table 50. Global Cancer Drugs Sales Market Share by Region (2021-2026) Table 51. Global Cancer Drugs Sales by Region (2027-2032) & (k tons) Table 52. Global Cancer Drugs Sales Market Share by Region (2027-2032) Table 53. Global Cancer Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 54. Global Cancer Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 55. Global Cancer Drugs Sales Value Share by Region (2021-2026) Table 56. Global Cancer Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 57. Global Cancer Drugs Sales Value Share by Region (2027-2032) Table 58. Global Cancer Drugs Market Average Price (US$/ton) by Region (2021-2026) Table 59. Global Cancer Drugs Market Average Price (US$/ton) by Region (2027-2032) Table 60. Global Cancer Drugs Sales by Country: 2021 VS 2025 VS 2032 (k tons) Table 61. Global Cancer Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Cancer Drugs Sales by Country (2021-2026) & (k tons) Table 63. Global Cancer Drugs Sales Market Share by Country (2021-2026) Table 64. Global Cancer Drugs Sales by Country (2027-2032) & (k tons) Table 65. Global Cancer Drugs Sales Market Share by Country (2027-2032) Table 66. Global Cancer Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 67. Global Cancer Drugs Sales Value Market Share by Country (2021-2026) Table 68. Global Cancer Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 69. Global Cancer Drugs Sales Value Market Share by Country (2027-2032) Table 70. Takeda Company Information Table 71. Takeda Business Overview Table 72. Takeda Cancer Drugs Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 73. Takeda Cancer Drugs Product Portfolio Table 74. Takeda Recent Development Table 75. Eisai Company Information Table 76. Eisai Business Overview Table 77. Eisai Cancer Drugs Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 78. Eisai Cancer Drugs Product Portfolio Table 79. Eisai Recent Development Table 80. Teva Company Information Table 81. Teva Business Overview Table 82. Teva Cancer Drugs Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 83. Teva Cancer Drugs Product Portfolio Table 84. Teva Recent Development Table 85. Sanofi Company Information Table 86. Sanofi Business Overview Table 87. Sanofi Cancer Drugs Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 88. Sanofi Cancer Drugs Product Portfolio Table 89. Sanofi Recent Development Table 90. Johnson & Johnson Company Information Table 91. Johnson & Johnson Business Overview Table 92. Johnson & Johnson Cancer Drugs Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 93. Johnson & Johnson Cancer Drugs Product Portfolio Table 94. Johnson & Johnson Recent Development Table 95. Novartis Company Information Table 96. Novartis Business Overview Table 97. Novartis Cancer Drugs Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 98. Novartis Cancer Drugs Product Portfolio Table 99. Novartis Recent Development Table 100. Roche Company Information Table 101. Roche Business Overview Table 102. Roche Cancer Drugs Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 103. Roche Cancer Drugs Product Portfolio Table 104. Roche Recent Development Table 105. Eli Lilly Company Information Table 106. Eli Lilly Business Overview Table 107. Eli Lilly Cancer Drugs Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 108. Eli Lilly Cancer Drugs Product Portfolio Table 109. Eli Lilly Recent Development Table 110. Pfizer Company Information Table 111. Pfizer Business Overview Table 112. Pfizer Cancer Drugs Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 113. Pfizer Cancer Drugs Product Portfolio Table 114. Pfizer Recent Development Table 115. Bayer Company Information Table 116. Bayer Business Overview Table 117. Bayer Cancer Drugs Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 118. Bayer Cancer Drugs Product Portfolio Table 119. Bayer Recent Development Table 120. Amgen Company Information Table 121. Amgen Business Overview Table 122. Amgen Cancer Drugs Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 123. Amgen Cancer Drugs Product Portfolio Table 124. Amgen Recent Development Table 125. AbbVie Company Information Table 126. AbbVie Business Overview Table 127. AbbVie Cancer Drugs Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 128. AbbVie Cancer Drugs Product Portfolio Table 129. AbbVie Recent Development Table 130. AstraZeneca Company Information Table 131. AstraZeneca Business Overview Table 132. AstraZeneca Cancer Drugs Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 133. AstraZeneca Cancer Drugs Product Portfolio Table 134. AstraZeneca Recent Development Table 135. Otsuka Company Information Table 136. Otsuka Business Overview Table 137. Otsuka Cancer Drugs Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 138. Otsuka Cancer Drugs Product Portfolio Table 139. Otsuka Recent Development Table 140. Merck KGaA Company Information Table 141. Merck KGaA Business Overview Table 142. Merck KGaA Cancer Drugs Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 143. Merck KGaA Cancer Drugs Product Portfolio Table 144. Merck KGaA Recent Development Table 145. Merck & Co. Company Information Table 146. Merck & Co. Business Overview Table 147. Merck & Co. Cancer Drugs Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 148. Merck & Co. Cancer Drugs Product Portfolio Table 149. Merck & Co. Recent Development Table 150. Ipsen Company Information Table 151. Ipsen Business Overview Table 152. Ipsen Cancer Drugs Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 153. Ipsen Cancer Drugs Product Portfolio Table 154. Ipsen Recent Development Table 155. Gilead Sciences Company Information Table 156. Gilead Sciences Business Overview Table 157. Gilead Sciences Cancer Drugs Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 158. Gilead Sciences Cancer Drugs Product Portfolio Table 159. Gilead Sciences Recent Development Table 160. Celgene Company Information Table 161. Celgene Business Overview Table 162. Celgene Cancer Drugs Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 163. Celgene Cancer Drugs Product Portfolio Table 164. Celgene Recent Development Table 165. Bristol-Myers Squibb Company Information Table 166. Bristol-Myers Squibb Business Overview Table 167. Bristol-Myers Squibb Cancer Drugs Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 168. Bristol-Myers Squibb Cancer Drugs Product Portfolio Table 169. Bristol-Myers Squibb Recent Development Table 170. Biogen Idec Company Information Table 171. Biogen Idec Business Overview Table 172. Biogen Idec Cancer Drugs Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 173. Biogen Idec Cancer Drugs Product Portfolio Table 174. Biogen Idec Recent Development Table 175. Astellas Company Information Table 176. Astellas Business Overview Table 177. Astellas Cancer Drugs Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 178. Astellas Cancer Drugs Product Portfolio Table 179. Astellas Recent Development Table 180. Key Raw Materials Table 181. Raw Materials Key Suppliers Table 182. Cancer Drugs Distributors List Table 183. Cancer Drugs Customers List Table 184. Research Programs/Design for This Report Table 185. Authors List of This Report Table 186. Secondary Sources Table 187. Primary Sources List of Figures Figure 1. Cancer Drugs Product Image Figure 2. Global Cancer Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cancer Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Cancer Drugs Sales (2021-2032) & (k tons) Figure 5. Global Cancer Drugs Sales Average Price (US$/ton) & (2021-2032) Figure 6. Global Cancer Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Targeted Therapy Image Figure 10. Hormonal Therapy (Biologic Therapy) Image Figure 11. Chemotherapy Image Figure 12. Immunotherapy Image Figure 13. Others Image Figure 14. Global Cancer Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (k tons) Figure 15. Global Cancer Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Cancer Drugs Sales Volume Share by Type (2021-2032) Figure 17. Global Cancer Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Cancer Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Cancer Drugs Sales Value Share by Type (2021-2032) Figure 20. Blood Cancer Image Figure 21. Gastrointestinal Cancer Image Figure 22. Breast Cancer Image Figure 23. Prostate Cancer Image Figure 24. Respiratory/Lung Cancer Image Figure 25. Other Cancers Image Figure 26. Global Cancer Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (k tons) Figure 27. Global Cancer Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 28. Global Cancer Drugs Sales Volume Share by Application (2021-2032) Figure 29. Global Cancer Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global Cancer Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 31. Global Cancer Drugs Sales Value Share by Application (2021-2032) Figure 32. Global Cancer Drugs Sales by Region: 2021 VS 2025 VS 2032 (k tons) Figure 33. Global Cancer Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 34. Global Cancer Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 35. Global Cancer Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 36. North America Cancer Drugs Sales Value (2021-2032) & (US$ Million) Figure 37. North America Cancer Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Europe Cancer Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. Europe Cancer Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Asia-Pacific Cancer Drugs Sales Value (2021-2032) & (US$ Million) Figure 41. Asia-Pacific Cancer Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 42. South America Cancer Drugs Sales Value (2021-2032) & (US$ Million) Figure 43. South America Cancer Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 44. Middle East & Africa Cancer Drugs Sales Value (2021-2032) & (US$ Million) Figure 45. Middle East & Africa Cancer Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 46. USA Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. USA Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. USA Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Canada Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Canada Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Canada Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Mexico Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Mexico Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Mexico Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Germany Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Germany Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Germany Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. France Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. France Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. France Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. U.K. Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. U.K. Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. U.K. Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Italy Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Italy Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Italy Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Spain Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Spain Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Spain Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Russia Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Russia Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Russia Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Netherlands Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Netherlands Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Netherlands Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Nordic Countries Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Nordic Countries Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Nordic Countries Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. China Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. China Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. China Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Japan Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Japan Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Japan Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. South Korea Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. South Korea Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. South Korea Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. India Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. India Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. India Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Australia Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Australia Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Australia Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Southeast Asia Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Southeast Asia Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Southeast Asia Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Brazil Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Brazil Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Brazil Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Argentina Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Argentina Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Argentina Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Chile Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Chile Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Chile Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Colombia Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Colombia Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Colombia Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Peru Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Peru Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Peru Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Saudi Arabia Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Saudi Arabia Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Saudi Arabia Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Israel Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Israel Arabia Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Israel Arabia Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. UAE Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. UAE Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. UAE Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Turkey Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Turkey Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Turkey Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Iran Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Iran Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Iran Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Egypt Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 128. Egypt Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 129. Egypt Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 130. Cancer Drugs Value Chain Figure 131. Manufacturing Cost Structure Figure 132. Cancer Drugs Sales Mode & Process Figure 133. Direct Comparison with Distribution Share Figure 134. Distributors Profiles Figure 135. Years Considered Figure 136. Research Process Figure 137. Key Executives Interviewed

Scope & coverage.

Types
  • Targeted Therapy
  • Hormonal Therapy (Biologic Therapy)
  • Chemotherapy
  • Immunotherapy
  • Others
Applications
  • Blood Cancer
  • Gastrointestinal Cancer
  • Breast Cancer
  • Prostate Cancer
  • Respiratory/Lung Cancer
  • Other Cancers
Companies covered
  • Takeda
  • Eisai
  • Teva
  • Sanofi
  • Johnson & Johnson
  • Novartis
  • Roche
  • Eli Lilly
  • Pfizer
  • Bayer
  • Amgen
  • AbbVie
  • AstraZeneca
  • Otsuka
  • Merck KGaA
  • Merck & Co.
  • Ipsen
  • Gilead Sciences
  • Celgene
  • Bristol-Myers Squibb
  • Biogen Idec
  • Astellas

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Cancer Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Cancer Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Cancer Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Cancer Drugs Market Dynamics
  1. 2.1 Cancer Drugs Industry Trends
  2. 2.2 Cancer Drugs Industry Drivers
  3. 2.3 Cancer Drugs Industry Opportunities and Challenges
  4. 2.4 Cancer Drugs Industry Restraints
3 Cancer Drugs Market by Company
  1. 3.1 Global Cancer Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Cancer Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Cancer Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Cancer Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Cancer Drugs Company Ranking (2024-2026)
  6. 3.6 Global Cancer Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Cancer Drugs Company Product Type and Application
  8. 3.8 Global Cancer Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Cancer Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Cancer Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Cancer Drugs Market by Type
  1. 4.1 Cancer Drugs Type Introduction
  2. 4.1.1 Targeted Therapy
  3. 4.1.2 Hormonal Therapy (Biologic Therapy)
  4. 4.1.3 Chemotherapy
  5. 4.1.4 Immunotherapy
  6. 4.1.5 Others
  7. 4.2 Global Cancer Drugs Sales Volume by Type
  8. 4.2.1 Global Cancer Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Cancer Drugs Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Cancer Drugs Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Cancer Drugs Sales Value by Type
  12. 4.3.1 Global Cancer Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Cancer Drugs Sales Value by Type (2021-2032)
  14. 4.3.3 Global Cancer Drugs Sales Value Share by Type (2021-2032)
5 Cancer Drugs Market by Application
  1. 5.1 Cancer Drugs Application Introduction
  2. 5.1.1 Blood Cancer
  3. 5.1.2 Gastrointestinal Cancer
  4. 5.1.3 Breast Cancer
  5. 5.1.4 Prostate Cancer
  6. 5.1.5 Respiratory/Lung Cancer
  7. 5.1.6 Other Cancers
  8. 5.2 Global Cancer Drugs Sales Volume by Application
  9. 5.2.1 Global Cancer Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  10. 5.2.2 Global Cancer Drugs Sales Volume by Application (2021-2032)
  11. 5.2.3 Global Cancer Drugs Sales Volume Share by Application (2021-2032)
  12. 5.3 Global Cancer Drugs Sales Value by Application
  13. 5.3.1 Global Cancer Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  14. 5.3.2 Global Cancer Drugs Sales Value by Application (2021-2032)
  15. 5.3.3 Global Cancer Drugs Sales Value Share by Application (2021-2032)
6 Cancer Drugs Regional Sales and Value Analysis
  1. 6.1 Global Cancer Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Cancer Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Cancer Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Cancer Drugs Sales by Region (2027-2032)
  5. 6.3 Global Cancer Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Cancer Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Cancer Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Cancer Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Cancer Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Cancer Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Cancer Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Cancer Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Cancer Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Cancer Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Cancer Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Cancer Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Cancer Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Cancer Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Cancer Drugs Sales Value Share by Country, 2025 VS 2032
7 Cancer Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Cancer Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Cancer Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Cancer Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Cancer Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Cancer Drugs Sales by Country (2027-2032)
  6. 7.4 Global Cancer Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Cancer Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Cancer Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Cancer Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Cancer Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Cancer Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Cancer Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Cancer Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Cancer Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Cancer Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Cancer Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Cancer Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Cancer Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Cancer Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Cancer Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Cancer Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Cancer Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Cancer Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Cancer Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Cancer Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Cancer Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Cancer Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Cancer Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Cancer Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Cancer Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Cancer Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Cancer Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Cancer Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Cancer Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Cancer Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Cancer Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Cancer Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda
  2. 8.1.1 Takeda Company Information
  3. 8.1.2 Takeda Business Overview
  4. 8.1.3 Takeda Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Cancer Drugs Product Portfolio
  6. 8.1.5 Takeda Recent Developments
  7. 8.2 Eisai
  8. 8.2.1 Eisai Company Information
  9. 8.2.2 Eisai Business Overview
  10. 8.2.3 Eisai Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Eisai Cancer Drugs Product Portfolio
  12. 8.2.5 Eisai Recent Developments
  13. 8.3 Teva
  14. 8.3.1 Teva Company Information
  15. 8.3.2 Teva Business Overview
  16. 8.3.3 Teva Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Teva Cancer Drugs Product Portfolio
  18. 8.3.5 Teva Recent Developments
  19. 8.4 Sanofi
  20. 8.4.1 Sanofi Company Information
  21. 8.4.2 Sanofi Business Overview
  22. 8.4.3 Sanofi Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Sanofi Cancer Drugs Product Portfolio
  24. 8.4.5 Sanofi Recent Developments
  25. 8.5 Johnson & Johnson
  26. 8.5.1 Johnson & Johnson Company Information
  27. 8.5.2 Johnson & Johnson Business Overview
  28. 8.5.3 Johnson & Johnson Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Johnson & Johnson Cancer Drugs Product Portfolio
  30. 8.5.5 Johnson & Johnson Recent Developments
  31. 8.6 Novartis
  32. 8.6.1 Novartis Company Information
  33. 8.6.2 Novartis Business Overview
  34. 8.6.3 Novartis Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Novartis Cancer Drugs Product Portfolio
  36. 8.6.5 Novartis Recent Developments
  37. 8.7 Roche
  38. 8.7.1 Roche Company Information
  39. 8.7.2 Roche Business Overview
  40. 8.7.3 Roche Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Roche Cancer Drugs Product Portfolio
  42. 8.7.5 Roche Recent Developments
  43. 8.8 Eli Lilly
  44. 8.8.1 Eli Lilly Company Information
  45. 8.8.2 Eli Lilly Business Overview
  46. 8.8.3 Eli Lilly Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Eli Lilly Cancer Drugs Product Portfolio
  48. 8.8.5 Eli Lilly Recent Developments
  49. 8.9 Pfizer
  50. 8.9.1 Pfizer Company Information
  51. 8.9.2 Pfizer Business Overview
  52. 8.9.3 Pfizer Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Pfizer Cancer Drugs Product Portfolio
  54. 8.9.5 Pfizer Recent Developments
  55. 8.10 Bayer
  56. 8.10.1 Bayer Company Information
  57. 8.10.2 Bayer Business Overview
  58. 8.10.3 Bayer Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Bayer Cancer Drugs Product Portfolio
  60. 8.10.5 Bayer Recent Developments
  61. 8.11 Amgen
  62. 8.11.1 Amgen Company Information
  63. 8.11.2 Amgen Business Overview
  64. 8.11.3 Amgen Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Amgen Cancer Drugs Product Portfolio
  66. 8.11.5 Amgen Recent Developments
  67. 8.12 AbbVie
  68. 8.12.1 AbbVie Company Information
  69. 8.12.2 AbbVie Business Overview
  70. 8.12.3 AbbVie Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 AbbVie Cancer Drugs Product Portfolio
  72. 8.12.5 AbbVie Recent Developments
  73. 8.13 AstraZeneca
  74. 8.13.1 AstraZeneca Company Information
  75. 8.13.2 AstraZeneca Business Overview
  76. 8.13.3 AstraZeneca Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 AstraZeneca Cancer Drugs Product Portfolio
  78. 8.13.5 AstraZeneca Recent Developments
  79. 8.14 Otsuka
  80. 8.14.1 Otsuka Company Information
  81. 8.14.2 Otsuka Business Overview
  82. 8.14.3 Otsuka Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Otsuka Cancer Drugs Product Portfolio
  84. 8.14.5 Otsuka Recent Developments
  85. 8.15 Merck KGaA
  86. 8.15.1 Merck KGaA Company Information
  87. 8.15.2 Merck KGaA Business Overview
  88. 8.15.3 Merck KGaA Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Merck KGaA Cancer Drugs Product Portfolio
  90. 8.15.5 Merck KGaA Recent Developments
  91. 8.16 Merck & Co.
  92. 8.16.1 Merck & Co. Company Information
  93. 8.16.2 Merck & Co. Business Overview
  94. 8.16.3 Merck & Co. Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Merck & Co. Cancer Drugs Product Portfolio
  96. 8.16.5 Merck & Co. Recent Developments
  97. 8.17 Ipsen
  98. 8.17.1 Ipsen Company Information
  99. 8.17.2 Ipsen Business Overview
  100. 8.17.3 Ipsen Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Ipsen Cancer Drugs Product Portfolio
  102. 8.17.5 Ipsen Recent Developments
  103. 8.18 Gilead Sciences
  104. 8.18.1 Gilead Sciences Company Information
  105. 8.18.2 Gilead Sciences Business Overview
  106. 8.18.3 Gilead Sciences Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Gilead Sciences Cancer Drugs Product Portfolio
  108. 8.18.5 Gilead Sciences Recent Developments
  109. 8.19 Celgene
  110. 8.19.1 Celgene Company Information
  111. 8.19.2 Celgene Business Overview
  112. 8.19.3 Celgene Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Celgene Cancer Drugs Product Portfolio
  114. 8.19.5 Celgene Recent Developments
  115. 8.20 Bristol-Myers Squibb
  116. 8.20.1 Bristol-Myers Squibb Company Information
  117. 8.20.2 Bristol-Myers Squibb Business Overview
  118. 8.20.3 Bristol-Myers Squibb Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  119. 8.20.4 Bristol-Myers Squibb Cancer Drugs Product Portfolio
  120. 8.20.5 Bristol-Myers Squibb Recent Developments
  121. 8.21 Biogen Idec
  122. 8.21.1 Biogen Idec Company Information
  123. 8.21.2 Biogen Idec Business Overview
  124. 8.21.3 Biogen Idec Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  125. 8.21.4 Biogen Idec Cancer Drugs Product Portfolio
  126. 8.21.5 Biogen Idec Recent Developments
  127. 8.22 Astellas
  128. 8.22.1 Astellas Company Information
  129. 8.22.2 Astellas Business Overview
  130. 8.22.3 Astellas Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  131. 8.22.4 Astellas Cancer Drugs Product Portfolio
  132. 8.22.5 Astellas Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Cancer Drugs Value Chain Analysis
  2. 9.1.1 Cancer Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Cancer Drugs Sales Mode & Process
  6. 9.2 Cancer Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Cancer Drugs Distributors
  9. 9.2.3 Cancer Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst